Central Pharmaceuticals Statistics
Total Valuation
Central Pharmaceuticals has a market cap or net worth of BDT 1.74 billion. The enterprise value is 2.02 billion.
Market Cap | 1.74B |
Enterprise Value | 2.02B |
Important Dates
The next estimated earnings date is Thursday, October 31, 2024.
Earnings Date | Oct 31, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Central Pharmaceuticals has 119.80 million shares outstanding. The number of shares has increased by 2.36% in one year.
Shares Outstanding | 119.80M |
Shares Change (YoY) | +2.36% |
Shares Change (QoQ) | -2.51% |
Owned by Insiders (%) | 25.89% |
Owned by Institutions (%) | n/a |
Float | 88.79M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 15.91 |
PB Ratio | 2.04 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -34.18 |
EV / Sales | 18.10 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 33.71.
Current Ratio | 1.18 |
Quick Ratio | 0.34 |
Debt / Equity | 33.71 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -2.49 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | 1.51M |
Profits Per Employee | -799,609 |
Employee Count | 74 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.00% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +16.00% |
50-Day Moving Average | 18.30 |
200-Day Moving Average | 21.37 |
Relative Strength Index (RSI) | 34.41 |
Average Volume (20 Days) | 1,174,386 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Central Pharmaceuticals had revenue of BDT 111.75 million and -59.17 million in losses. Loss per share was -0.48.
Revenue | 111.75M |
Gross Profit | -15.15M |
Operating Income | -45.14M |
Pretax Income | -63.26M |
Net Income | -59.17M |
EBITDA | -20.65M |
EBIT | -45.14M |
Loss Per Share | -0.48 |
Balance Sheet
The company has 1.18 million in cash and 286.60 million in debt, giving a net cash position of -285.42 million or -2.38 per share.
Cash & Cash Equivalents | 1.18M |
Total Debt | 286.60M |
Net Cash | -285.42M |
Net Cash Per Share | -2.38 |
Equity (Book Value) | 850.24M |
Book Value Per Share | 7.10 |
Working Capital | 67.15M |
Cash Flow
Operating Cash Flow | -126,003 |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is -13.56%, with operating and profit margins of -40.40% and -52.95%.
Gross Margin | -13.56% |
Operating Margin | -40.40% |
Pretax Margin | -56.61% |
Profit Margin | -52.95% |
EBITDA Margin | -18.48% |
EBIT Margin | -40.40% |
FCF Margin | n/a |
Dividends & Yields
Central Pharmaceuticals does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.36% |
Shareholder Yield | -2.36% |
Earnings Yield | -3.33% |
FCF Yield | n/a |
Stock Splits
The last stock split was on November 26, 2018. It was a forward split with a ratio of 1.05.
Last Split Date | Nov 26, 2018 |
Split Type | Forward |
Split Ratio | 1.05 |